Female genital tract malignancy is the most common carcinoma. Around 70,000 new cases of
uterine cancers and 75,000 new cases of breast cancers are reported in India every year. In the
developed countries ovarian cancer is the most common cancer and in developing countries,
carcinoma cervix is the most common malignancy. As per the national centre for health statistics,
cancer is the second leading cause of death amongst women aged between 25-44 years. One of
the common sites of tumours in females is the female genital tract. The few common sites are
cervix, ovary and endometrium. These malignancies are seen worldwide but their distribution
varies from one place to another. Around 75% of the ovarian cancer patients report with
advanced stage of disease leading to increased mortality. In the present era, due to the presence
of advanced screening and treatment modalities in developed countries, there has been a drastic
decline in the incidence and mortality associated with cervical cancer. On the contrary, in
developing countries due to low resources and lack of awareness there hasn't been much
improvement in the screening programmes. People of rural areas do not have much access to the
health care services due to which cervical cancer is the most common genital carcinoma in
developing countries.
MEANING: Reproductive tract malignancies means malignancy start in the organs related to
reproduction. These organs are located in the pelvis. Female genital tract is most common site
for tumours in females. The most common type of female genital tract cancers are – cervical,
ovarian and endometrial carcinoma. There are other less common tumours including tumours of
vagina, vulva and fallopian tubes. (Blaustein’s Pathology of the Female Genital Tract, 2002).
DEFINITION: Cancers can occur in any part of the female reproductive system—the vulva,
vagina, cervix, uterus, fallopian tubes, or ovaries. These cancers are called gynecologic cancers
or reproductive tract malignancies. Gynecologic cancers can directly invade nearby tissues and
organs or spread (metastasize) through the lymphatic vessels and lymph nodes (lymphatic
system) or bloodstream to distant parts of the body.
Cancers of the female reproductive system - namely cancer of the cervix uteri (cervical cancer),
ovarian, vulvar, vaginal, fallopian tube cancers, and choriocarcinoma - are an important cause of
cancer morbidity and mortality worldwide. Cervical, endometrial, and ovarian cancers are
relatively common, whereas vulvar, vaginal, fallopian tube cancers, and choriocarcinomas are
very rare.
o Uterine Corpus Malignancy —begins in the uterus (womb), the organ where the baby grows
when a woman is pregnant.
o Ovarian Malignancy —begins in the ovaries, the two organs that make and house a woman's
eggs.
o Uterine Cervix Malignancy (Cervical Carcinoma) —begins in the cervix, the lower end of the
uterus that attaches to the vagina.
o Vulvar Malignancy —begins in the vulva, the area around the opening of the vagina.
o Vaginal Malignancy –begins in the vagina, the hollow channel that leads from the uterus to the
outside of the body.
Breast cancer is sometimes considered a reproductive cancer too. Breast cancer begins in the
tissues that make up the breast.
INCIDENCE:
Female genital tract malignancies have worldwide distribution, but vary from one region to
another. Dinshaw Nene et al. (1997) did population based rural cancer registry in Barshi,
Paranda and Bhum areas in Maharastra under the National Cancer Registry Programme of
ICMR. According to this registry the leading site of cancer in females was cancer cervix (50.7%)
the most common site followed by cancer breast (15.1%), esophagus (4.2%), ovary (2.2%) oral
cavity and stomach (1.4%).
The Uterine corpus malignancy represents the second most common site for malignancy of the
female genital systems. Endometrial carcinoma occurs predominately in developed countries and
is frequently associated with obesity.
Cervical carcinoma is the second most common cancer in women worldwide and the most
common female genital cancer in the developing countries. More than 85% of the global burden
of cervical cancer occurs in less developed regions, where it accounts for 13% of all cancers in
women.
Tumours of the ovary represent about 30% of all cancers of female genital tract. Ovarian cancer
is a major cause of death from female genital tract malignancies. About 75% of the patients with
ovarian cancer present with advanced stages of the disease due to nonspecific symptoms of the
disease and failure to detect the tumor early.
Cancer of the vagina is relatively rare, accounting for about 1%- 2% of gynaecological
malignancies.
The vulva is formed by the labia majora , labia minora, clitoris , mons pubis and the associated
structures of the vestibule including the urethral meatus. Benign tumours of vulva including
condyloma acumintum and others. Squamous cell carcinoma is the most common malignant
tumours of the vulva occurs predominantly in older age group.
So far, the etiology of cancers of the female reproductive system has been primarily
attributed to lifestyle factors.
Ovarian cancer
Cervical carcinoma:
Cervical cancer is caused by persistent infection with human papilloma virus (HPV)
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, or 59;
persistent infections with HPV16 and 18 cause about 70% of all cervical cancers
worldwide.
Persistent infection with HPV types 26, 53, 66, 67, 68, 70, 73, or 82 may also be causally
related to cervical cancer.
Other exposures that are considered carcinogenic to the cervix uteri are in utero exposure
to diethylstilbestrol (associated with SCC of the cervix), use of combined estrogen-
progestogen oral contraceptives (associated with both in situ and invasive cervical
cancer), human immunodeficiency virus type 1 (HIV1) infection, and tobacco smoking.
Vulvular carcinoma:
The etiology remains unclear. But the following factors are often related.
Vaginal carcinoma:
Unfortunately, researchers do not yet know the exact causes of vaginal cancer. They have,
however, identified several risk factors for developing vaginal cancer. These risk factors include:
*Simplified from the International Federation of Gynecology and Obstetrics Staging System.
†Stage IV is sometimes further classified as A or B depending on where the cancer has spread.
‡The pelvis refers the lowest part of the torso, the area below the abdomen and between the hip bones.
It contains the internal reproductive organs, bladder, and rectum.
Early signs of reproductive tract malignancies: Each type of reproductive cancer has
different symptoms.
o Uterine-vaginal bleeding or discharge that is not normal, pressure or pain in the pelvic area.
o Ovarian-vaginal bleeding or discharge that is not normal, pressure or pain in the pelvic area,
belly or back, bloating.
o Vulvar-pressure or pain in the pelvic area, itching, burning, rash, or sores around the opening of
the vagina.
SCREENING & DIAGNOSIS:
Among all three of these reproductive-system cancers, early detection is crucial. But detection
can be very difficult, especially in the early stages.
o Regular pelvic examinations and (Pap) tests or other similar tests can lead to the early detection
of certain gynecologic cancers, especially cancer of the cervix. Such examinations can
sometimes prevent cancer by detecting precancerous changes (dysplasia) before they become
cancer.
o Regular pelvic examinations can also detect early cancers of the vagina and vulva. However,
cancers of the ovaries, uterus, and fallopian tubes are not easy for doctors to detect during a
pelvic examination.
o If cancer is diagnosed, one or more procedures may be done to determine the stage of the cancer.
The stage is based on how large the cancer is and how far it has spread.
TREATMENT
o Reproductive cancers are often treated with surgery, chemotherapy (medicine to kill cancer
cells), hormone therapy (medicine to block hormones that are related to cancer growth), or
radiation.
o The main treatment of endometrial or ovarian cancer is surgical removal of the tumor. Surgery
may be followed by radiation therapy or chemotherapy.
o In women with cervical cancer, radiation therapy may be external (using a large machine) or
internal (using radioactive implants placed directly on the cancer). External radiation therapy is
usually given several days a week for several weeks. Internal radiation therapy involves staying
in the hospital for several days while the implants are in place.
o Chemotherapy may be given by injection, by mouth, or through a catheter inserted into the
abdomen (intraperitoneally). How often chemotherapy is given depends on the type of cancer.
Sometimes women have to remain at the hospital while they receive chemotherapy.
o When a gynecologic cancer is very advanced and a cure is not possible, radiation therapy or
chemotherapy may still be recommended to reduce the size of the cancer or its metastases and to
relieve pain and other symptoms.
o Appropriate drugs can be used to relieve the anxiety and pain commonly experienced by people
with incurable cancer.
o (Cervical) Combination Therapy: There was a major advance in the treatment of cervical
cancer when five NCI-sponsored clinical trials showed that patients with advanced cervical
cancer who were treated with combination chemo based on the drug cisplatin, together with
radiation therapy, survived significantly longer than patients who were treated with radiation
therapy alone. The overall results from these trials showed that the risk of death from cervical
cancer was decreased by about 30 percent — down to a 50 percent risk of death — with the use
of this concurrent "chemoradiation" therapy. In light of these findings, NCI issued a clinical
announcement to thousands of physicians stating that strong consideration should be given to
adding chemotherapy to radiation therapy in the treatment of invasive cervical cancer.
o (Cervical) HPV vaccine: Another major advance in the management of cervical cancer was the
FDA's approval of a vaccine designed specifically to prevent this disease. The results of several
studies have shown that in women who had not already been infected, the approved HPV vaccine
was nearly 100 percent effective in preventing precancerous cervical lesions, precancerous
vaginal and vulvar lesions, and genital warts caused by infection with the types of human
papilloma virus (HPV) targeted by the vaccine.
PREVENTION
KEY POINTS
Avoiding risk factors and increasing protective factors may help prevent cancer.
o Avoiding cancer risk factors may help prevent certain cancers. Risk factors include
smoking, being overweight, and not getting enough exercise. Increasing protective
factors such as quitting smoking and exercising may also help prevent some cancers.
o Education regarding the significance of irregular bleeding per vagina in
perimenopausal and postmenopausal period.
o Screening of high risk women at least in menopausal period to detect the premalignant
or early carcinoma is a positive step.
The following protective factors decrease the risk of cancer:
DEFINITION: Pelvic inflammatory disease, or PID, is a disease of the upper genital tract. It is a
spectrum of infection and inflammation of the upper genital tract organs typically involving the
uterus, ovaries, fallopian tubes, and cervix. It’s usually caused by a sexually transmitted infection
(STI), like chlamydia or gonorrhea, and is treated with antibiotics.
CAUSES
Many types of bacteria can cause PID, but gonorrhea or chlamydia infections are the most
common. These bacteria are usually acquired during unprotected sex. The bacteria first enter the
vagina and cause an infection. As time passes, this infection can move into the pelvic organs.PID
can become extremely dangerous, even life-threatening, if the infection spreads to your blood.
RISK FACTORS
A number of factors might increase the risk of pelvic inflammatory disease, including:
Being in a sexual relationship with a person who has more than one sex partner
Douching regularly, which upsets the balance of good versus harmful bacteria in the
vagina and might mask symptoms
Minimum criteria:
Lower abdominal tenderness
Cervical motion tenderness
Additional criteria:
Definitive criteria
INVESTIGATIONS:
Blood and urine tests. These tests will measure your white blood cell count, which
might indicate an infection, and markers that suggest inflammation. Your doctor also
might recommend tests for HIV and sexually transmitted infections, which are sometimes
associated with PID.
Ultrasound. This test uses sound waves to create images of your reproductive organs.
Laparoscopy. Laproscopy is considered the “gold standard”. While it is the most reliable
aid to support the clinical diagnosis.
COMPLICATIONS OF PID:
Immediate:
1. Pelvic
2. Septicemia – producing arthritis or myocarditis.
Late:
Infertility. PID might damage your reproductive organs and cause infertility — the
inability to become pregnant. The more times you've had PID, the greater your risk of
infertility. Delaying treatment for PID also dramatically increases your risk of infertility.
Chronic pelvic pain. Pelvic inflammatory disease can cause pelvic pain that might last for
months or years. Scarring in your fallopian tubes and other pelvic organs can cause pain
during intercourse and ovulation.
PREVENTION
To reduce your risk of pelvic inflammatory disease, essential steps in the prevention are:
Community based approach to increase public health awareness.
Prevention of sexually transmitted diseases with the knowledge of healthy and safe sex.
Plan : At the end of the shiftthe patient will be ableto report a decrease of pain.
Intervention:
- Discuss impact of painon lifestyle /independence and waysto maximize level of functioning.
- Identify specific signs /symptoms and changesin pain characteristicsrequiring medical follow up.
UTERINE FIBROID:
Fibroids are muscular tumors that grow in the wall of the uterus (womb). Another medical term
for fibroids is “leiomyoma” (leye-oh-meye-OHmuh) or just “myoma”. Fibroids are almost
always benign (not cancerous). Fibroids can grow as a single tumor, or there can be many of
them in the uterus. They can be as small as an apple seed or as big as a grapefruit. In unusual
cases they can become very large.
DEFINITION: Uterine fibroids, also known as uterine leiomyomas or fibroids, are benign
smoothmuscle tumors of the uterus. Most women have no symptoms while others may have
painful or heavy periods. If large enough, they may push on the bladder causing a frequent need
to urinate. They may also cause pain during sex or lower back pain. A woman can have one
uterine fibroid or many of them. Occasionally, fibroids may make it difficult to get pregnant,
although this is uncommon.
Incidence: About 20% to 80% of women develop fibroids by the age of 50. In 2013, it was
estimated that 171 million women were affected. They are typically found during the middle and
later reproductive years. After menopause, they usually decrease in size. In the United States,
uterine fibroids are a common reason for surgical removal of the uterus.
Location and classification
Growth and location are the main factors that determine if a fibroid leads to symptoms and
problems. A small lesion can be symptomatic if located within the uterine cavity while a large
lesion on the outside of the uterus may go unnoticed. Different locations are classified as
follows:
Intramural fibroids are located within the wall of the uterus and are the most common
type; unless large, they may be asymptomatic.
Subserosal fibroids are located underneath the peritoneal surface of the uterus and can
become very large.
Submucosal fibroids are located in the muscle beneath the endometrium of the uterus
and distort the uterine cavity; even small lesions in this location may lead to bleeding and
infertility.
Cervical fibroids are located in the wall of the cervix (neck of the uterus). Rarely,
fibroids are found in the supporting structures of the uterus that also contain smooth
muscle tissue.
Fibroids may be single or multiple. Most fibroids start in the muscular wall of the uterus. With
further growth, some lesions may develop towards the outside of the uterus or towards the
internal cavity. Secondary changes that may develop within fibroids are hemorrhage, necrosis,
calcification, and cystic changes. They tend to calcify after menopause.
If the uterus contains too many to count, it is referred to as diffuse uterine leiomyomatosis.
Pathophysiology:
An enucleated uterine leiomyoma – external surface on left, cut surface on right.
Fibroids are a type of uterine leiomyoma. Fibroids grossly appear as round, well circumscribed
solid nodules that are white or tan, and show whorled appearance on histological section. The
size varies, from microscopic to lesions of considerable size. Typically lesions the size of a
grapefruit or bigger are felt by the patient herself through the abdominal wall.
ETIOLOGY: The exact cause is generally unknown but certain predisposing factors are
responsible.
Predisposing factors includes:
Obesity
Hereditary
Genetic Disorder
CLINICAL MANIFESTATION:
(6) infertility
CLINICAL PRESENTATION:
uterine size is much bigger than the period of amenorrhoea
less foetal movements
foetal heart not felt easily
pelvic examination
Ultrasonography
MRI, CTG
Weight monitoring.
Sonohysterography Hysterosalpingography
Hematological assessment
MEDICAL MANAGEMENT:
Most fibroids do not require treatment unless they are causing symptoms. After menopause
fibroids shrink and it is unusual for them to cause problems.
Medication:
Hysterectomy: was the classical method of treating fibroids. Although it is now recommended
only as last option, fibroids are still the leading cause of hysterectomies in the US.
cord compression
musculoskeletal abnormalities
hydro nephrosis
intrauterine growth restriction
prolonged labour
NURSING MANAGEMENT:-
Assessment of patient who is having uterine fibroid is usually based on clinical manifestations
that usually occur. The nursing interventions required by the patient with uterine fibroid vary
greatly depending on the severity of the disease. Nursing intervention is based on nursing
process.
Nursing Diagnosis:
Feeling discomfort in spine position uterine height more than the gestational age
Nursing Diagnosis:
Plan: to monitor vital signs, observe skin color, Oxygen saturation, skin temperature and loss of
consciousness, evaluate the amount of vaginal bleeding.
Intervention:
Take plenty of fluids and fruits containing good content of water like watermelon.
Monitor intake and output strictly; notify health care provider if urine output is less than
30 mL/hour.
Monitor vital signs every hour.
Evaluation: Client’s vital signs were normal.
Nursing Diagnosis II: Altered position related to gravid uterus and fibroid
Nursing Diagnosis III: Anxiety related to diagnosis and concern for self care.
Plan: To Decrease Anxiety and Increase Knowledge.
Intervention:
BREAST CARCINOMA
Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women. In
less-developed countries, it is the leading cause of cancer death in women. In developed
countries, however, it has been surpassed by lung cancer as a cause of cancer death in women. In
the United States, breast cancer accounts for 29% of all cancers in women and is second only to
lung cancer as a cause of cancer deaths. (For discussion of male breast cancer, see Breast Cancer
in Men.)
Breast carcinoma is a cancer that develops from breast tissue. Early breast carcinomas are
asymptomatic; pain or discomfort is not usually a symptom of breast cancer. Breast cancer is
often first detected as an abnormality on a mammogram before it is felt by the patient or
healthcare provider.
The general approach to evaluation of breast cancer has become formalized as triple assessment:
clinical examination, imaging (usually mammography, ultrasonography, or both), and needle
biopsy. Increased public awareness and improved screening have led to earlier diagnosis, at
stages amenable to complete surgical resection and curative therapies. Improvements in therapy
and screening have led to improved survival rates for women diagnosed with breast cancer.
RISK FACTORS:
Environmental risk factors: Tobacco smoke (both active and passive exposure),Alcohol
consumption, Environmental carcinogens (eg, exposure to pesticides, radiation, and
environmental and dietary estrogens).
SIGNS AND SYMPTOMS:
Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the
skin, fluid coming from the nipple, or a red scaly patch of skin. In those with distant spread of
the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.
Breast cancer
The first noticeable symptom of breast cancer is typically a lump that feels different from the rest
of the breast tissue. Indications of breast cancer other than a lump may include thickening
different from the other breast tissue, one breast becoming larger or lower, a nipple changing
position or shape or becoming inverted, skin puckering or dimpling, a rash on or around a nipple,
discharge from nipple/s, constant pain in part of the breast or armpit, and swelling beneath the
armpit or around the collarbone.
DIAGNOSIS:
Most types of breast cancer are easy to diagnose by microscopic analysis of a sample—
or biopsy—of the affected area of the breast.
PREVENTION
Life-style
Women may reduce their risk of breast cancer by maintaining a healthy weight, drinking less
alcohol, being physically active and breastfeeding their children. Strategies that encourage
regular physical activity and reduce obesity could also have other benefits, such as reduced risks
of cardiovascular disease and diabetes. High intake of citrus fruit has been associated with a 10%
reduction in the risk of breast cancer.
Medications
The selective estrogen receptor modulators (such as tamoxifen) reduce the risk of breast cancer
but increase the risk of thromboembolism and endometrial cancer.[100][100] There is no overall
change in the risk of death. They are thus not recommended for the prevention of breast cancer in
women at average risk but may be offered for those at high risk.
Medication:
Drugs used after and in addition to surgery are called adjuvant therapy. Chemotherapy or other
types of therapy prior to surgery are called neoadjuvant therapy. Aspirin may reduce mortality
from breast cancer.
There are currently three main groups of medications used for adjuvant breast cancer treatment:
hormone-blocking agents, chemotherapy, and monoclonal antibodies.
Patient History. Assess the patient’s and family’s previous medical history of breast cancer or
other Cancers.
Palpation may identify a hard lump, mass, or thickening of breast tissue. Palpation of the
cervical supraclavicular and axillary nodes may also disclose lumps or enlargement.
Painless lump or mass in her breast or that she noticed a thickening of breast tissue
Examine the axillary and supraclavicular areas for enlarged nodes. You may note the tumor
is firm and immovable.
Assess the patient for pain or tenderness at the tumor site.
Inspect the breast skin for signs of advanced disease: the presence of inflammation, dimpling,
orange peel effect, distended vessels, and nipple changes or ulceration
Nursing diagnosis I: Acute pain related to Surgical procedure; tissue trauma, interruption of
nerves, dissection of muscles.
Nursing Interventions:
Pain Management:
Alleviation of pain or a reduction in pain to a level of comfort that is acceptable to the
patient.
Analgesic Administration: Use of pharmacologic agents to reduce or eliminate pain.
Environmental Management: Comfort: Manipulation of the patient’s surroundings for
promotion of optimal comfort
Evaluation:
Nursing diagnosis II: Anxiety related to change of body image; scarring, loss of body part,
sexual attractiveness extent of disease, impact on others; uncertainty of prognosis; denial of own
mortality Situational crisis.
Nursing Interventions:
Anxiety Reduction: Minimizing apprehension, dread, foreboding, or uneasiness related to
an unidentified source or anticipated danger.
Calming Technique: Reducing anxiety in patient experiencing acute distress
Evaluation: Express that she feels less anxious.
Nursing diagnosis III: Impaired skin integrity related to surgical removal of skin and tissue;
altered circulation, presence of edema, drainage; changes in skin elasticity, sensation; tissue
destruction of radiation therapy.
Nursing interventions:
Wound Care: Prevention of wound complications and promotion of wound healing.
Incision Site Care: Cleansing, monitoring, and promotion of healing in a wound that is
closed with sutures, clips, or staples.
Pressure Ulcer Care: Facilitation of healing in pressure ulcers
Evlauation:
Participate in her own care at the highest level possible within the limitations of her
illness.
Express positive feelings about self.
Urge the patient to avoid activities that could injure her arm and hand on the side of her
surgery. Caution her not to let blood be drawn from or allow injections into that arm. She
should also refuse to have blood pressure taken or I.V. therapy administered on the
affected arm.
REFERENCES: